NeuroEndocrine Cancer Australia CEO Meredith Cummins joined a panel discussion at the Medicines Australia Horizon Scanning event, accompanied by Media and External Relations Manager Ciara Connolly. The event brought together healthcare leaders, policymakers,
clinicians, and industry representatives to explore emerging opportunities in medicines and diagnostics, with a strong focus on genomics.
Meredith shared insights from the perspective of neuroendocrine cancer patients, highlighting the ongoing challenges in accessing treatments when PBS descriptors do not align with rare or less common cancer types. She emphasised the significant impact of delayed diagnoses, high out-of-pocket costs, and the lack of access to life-changing therapies available overseas. A key theme of the discussion was ensuring equitable access to all patients, regardless of the rarity of their cancer, and the importance of learning from international models to streamline approval and delivery processes in Australia.
The day’s conversations reinforced the critical role of genomics in shaping the future of personalised medicine. Attendees expressed excitement about the potential of Genomics Australia to enhance early diagnosis, target therapies more effectively, and align Australian practices with global standards, particularly the UK. The discussions also highlighted the importance of patient engagement, transparency in treatment costs, and developing a health system agile enough to adopt new therapies while supporting infrastructure, workforce, and equitable distribution across the country.
NeuroEndocrine Cancer Australia was pleased to network with other stakeholders, participate in panels and talks, and contribute to shaping strategies that could improve patient outcomes and access to precision therapies.
